NuCana (NCNA) executive details large option grants in Form 3

Rhea-AI Filing Summary

NuCana plc executive David James Harrison, Head of Translational Medicine, filed an initial Form 3 reporting holdings of options over the company’s Ordinary Shares. The filing lists several option grants, including options over 62,499,995 Ordinary Shares with a 0.004 Pounds Sterling exercise price that fully vested on June 20, 2025 and expire on June 20, 2035.

Other grants referenced include options over 1,971,417, 77,520,679 and 64,471,412 Ordinary Shares at a 0.0004 Pounds Sterling exercise price, with vesting completed on June 20, 2025 or January 14, 2026, and new awards vesting 25% on June 20, 2026 and January 14, 2027 with the remainder in three equal annual installments, subject to continued service.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Harrison David James

(Last) (First) (Middle)

C/O NUCANA PLC

3 LOCHSIDE WAY

(Street)

EDINBURGH UNITED KINGDOM EH12 9DT

(City) (State) (Zip)

UNITED KINGDOM

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
NuCana plc [ NCNA ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Head of Translational Medicine

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Options	(1)	(1)	Ordinary Shares	62,499,995	(1)	D
Options	(2)	(2)	Ordinary Shares	1,971,417	(2)	D
Options	(3)	(3)	Ordinary Shares	77,520,679	(3)	D
Options	(4)	(4)	Ordinary Shares	64,471,412	(4)	D
Options	(5)	(5)	Ordinary Shares	77,520,679	(5)	D

Explanation of Responses:

1. The ordinary shares, nominal value 0.0004 Pounds Sterling per share (the "Ordinary Shares"), of NuCana plc (the "Company") underlying this option have an exercise price of 0.004 Pounds Sterling, completed vesting on June 20, 2025 and expire June 20, 2035.

2. The Ordinary Shares underlying this option have an exercise price of 0.0004 Pounds Sterling, completed vesting on June 20, 2025 and expire June 20, 2035.

3. The Ordinary Shares underlying this option have an exercise price of 0.0004 Pounds Sterling, completed vesting on January 14, 2026 and expire January 14, 2036.

4. The Ordinary Shares underlying this option have an exercise price of 0.0004 Pounds Sterling and will vest as to 25% on June 20, 2026, with the remainder vesting in three equal annual installments thereafter, subject to the Reporting Person's continued service with the Company through the applicable vesting date.

5. The Ordinary Shares underlying this option have an exercise price of 0.0004 Pounds Sterling and will vest as to 25% on January 14, 2027, with the remainder vesting in three equal annual installments thereafter, subject to the Reporting Person's continued service with the Company through the applicable vesting date.

Remarks:

This Form 3 is being filed late due to unanticipated delays in receiving the Reporting Person's EDGAR codes, which delays the Reporting Person understands were due to the high volume of applications at the time. Exhibit 24.1 - Power of Attorney

	/s/ Ian Webster, Attorney-in-Fact for David Harrison	03/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does NuCana (NCNA) disclose in David James Harrison’s Form 3?

The Form 3 shows David James Harrison holds multiple option grants over NuCana Ordinary Shares. These options carry very low exercise prices and various vesting and expiration dates extending through 2036, outlining his existing equity-based compensation position.

What are the key option terms reported by NuCana (NCNA) for David James Harrison?

Key terms include options over 62,499,995 Ordinary Shares at a 0.004 Pounds Sterling exercise price and additional grants at 0.0004 Pounds Sterling. Some options are fully vested, while others vest in stages, with expirations in 2035 and 2036.

When do David James Harrison’s NuCana (NCNA) options vest and expire?

Certain options completed vesting on June 20, 2025 and January 14, 2026 and expire on June 20, 2035 and January 14, 2036. Other grants vest 25% in 2026 or 2027, with the remainder vesting annually over the following three years.

Does NuCana’s Form 3 for David James Harrison show any stock purchases or sales?

The Form 3 is an initial ownership report and lists option holdings only. The transaction summary indicates no buy, sell, exercise, gift, or tax-withholding transactions, focusing solely on existing derivative positions over NuCana Ordinary Shares.

What role does David James Harrison hold at NuCana (NCNA) in this Form 3?

David James Harrison is identified as an officer of NuCana with the title Head of Translational Medicine. The Form 3 links his equity compensation, in the form of options over Ordinary Shares, to his ongoing service with the company.